Theodore Leng, MD, FACS

home / authors / theodore-leng-md-facs

Articles

The Future of Treatment for Diabetic Macular Edema

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

February 3rd 2022

Dr Theodore Leng discusses what the future may hold for patients with diabetic macular edema.

Emerging Treatment Options for Diabetic Macular Edema

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

January 27th 2022

Dr. Ehsan Rahimy describes the emerging treatment options for diabetic macular edema.

Diabetic Macular Edema: Faricimab

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

January 27th 2022

Joseph M. Coney, MD, provides an overview of the drug faricimab for treating diabetic macular edema.

Anti-VEGF Agents and Diabetic Retinopathy Severity Score

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

January 20th 2022

Retina specialists review clinical trial data on the impact of anti-VEGF agents on diabetic retinopathy severity scores.

Maintenance Treatment for Diabetic Macular Edema

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

January 20th 2022

Key opinion leaders describe maintenance treatments for diabetic macular edema and provide an overview of the PANORAMA study.

Considerations for Switching Diabetic Macular Edema Treatments

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

January 17th 2022

Ehsan Rahimy, MD, and Theodore Leng, MD, FACS, discuss how to assess patient response to treatment and when to switch agents.

Reviewing Anti-VEGF Agents in Clinical Practice

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

January 17th 2022

Dr Joseph M. Coney reviews his personal experience using anti-VEGF agents to treat diabetic macular edema in his clinical practice.

Diabetic Macular Edema: Limitations of Anti-VEGF Agents

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

January 17th 2022

Retina experts discuss the limitations of anti-VEGF agents in treating diabetic macular edema.

Anti-VEGF Agents for Diabetic Macular Edema

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

January 17th 2022

Theodore Leng, MD, FACS, describes the currently available anti-VEGF agents for treating diabetic macular edema and what factors to consider when choosing a therapy.

Treatment Options for Diabetic Macular Edema

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

December 30th 2021

Ehsan Rahimy, MD, and Joseph M. Coney, MD, review the available treatment options for diabetic macular edema.

Diabetic Macular Edema with Concomitant Conditions

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

December 30th 2021

A professor of ophthalmology describes how concomitant conditions with diabetic macular edema affect the urgency of treatment regimens.

Progression of Diabetic Macular Edema

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

December 23rd 2021

A panel of experts explains how diabetic macular edema progresses over time and how to educate patients about progression prevention.

Diagnostic Testing for Diabetic Macular Edema

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

December 23rd 2021

Dr Theodore Leng reviews the preferred testing options for diabetic macular edema.

Pathophysiology of Diabetic Macular Edema

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

December 16th 2021

Retina specialists describe how diabetic retinopathy leads to diabetic macular edema, and the pathophysiology of the condition.

An Overview of Diabetic Macular Edema

Nancy Holekamp, MD;Joseph M. Coney, MD;Theodore Leng, MD, FACS;Ehsan Rahimy, MD

December 16th 2021

Joseph M. Coney, MD, and Theodore Leng, MD, FACS, define diabetic macular edema and explain the typical symptoms to watch for and patient referral patterns.